Clinical Trial Update: A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) [Phase 2]

View source ↗

Summary

Phase 2 randomized trial assessing alternating imatinib with regorafenib versus imatinib alone as first-line therapy for advanced gastrointestinal stromal tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib (imatinib)
• Regorafenib (regorafenib)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Gastrointestinal Stromal Tumour | Phase 2 | Status: UNKNOWN